Apyx Medical Corporation (APYX)

NASDAQ: APYX · Real-Time Price · USD
3.940
+0.070 (1.81%)
At close: May 19, 2026, 4:00 PM EDT
3.940
0.00 (0.00%)
After-hours: May 19, 2026, 4:00 PM EDT
Market Cap167.32M +254.5%
Revenue (ttm)55.90M +18.2%
Net Income-9.17M
EPS-0.22
Shares Out 41.83M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume70,069
Open3.800
Previous Close3.870
Day's Range3.800 - 4.090
52-Week Range1.335 - 4.500
Beta1.35
AnalystsStrong Buy
Price Target6.50 (+62.5%)
Earnings DateMay 7, 2026

About APYX

Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparo... [Read more]

Sector Healthcare
IPO Date Jan 1, 1987
Employees 205
Stock Exchange NASDAQ
Ticker Symbol APYX
Full Company Profile

Financial Performance

In 2025, Apyx Medical's revenue was $52.84 million, an increase of 9.86% compared to the previous year's $48.10 million. Losses were -$11.21 million, -52.22% less than in 2024.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for APYX stock is "Strong Buy." The 12-month stock price target is $6.5, which is an increase of 62.50% from the latest price.

Price Target
$6.5
(62.50% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuction

CLEARWATER, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AY...

5 days ago - GlobeNewsWire

Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™

Addition of the power liposuction capability as a second advanced liposuction modality is expected to drive even greater market demand for AYON Addition of the power liposuction capability as a second...

8 days ago - GlobeNewsWire

Apyx Medical reports Q1 EPS (5c), consensus (11c)

Reports Q1 revenue $12.49M, consensus $10.77M. “Our first quarter results reflect continued execution against our commercial strategy, with strong revenue growth driven by adoption of AYON in the U.S....

12 days ago - TheFly

Apyx Medical raises FY26 revenue view to $59M-$60M from $57.5M-$58.5M

Consensus $57.84M. Backs FY26 operating expenses view less than $45M.

12 days ago - TheFly

Apyx Medical Earnings Call Transcript: Q1 2026

Q1 2026 revenue grew 32% year-over-year to $12.5M, led by AYON system sales and strong international demand. Gross margin improved to 63.5%, and full-year guidance was raised to $59–$60M. AYON adoption is early, with FDA clearance for power liposuction expected soon.

12 days ago - Transcripts

Apyx Medical Earnings release: Q1 2026

Apyx Medical released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.

12 days ago - Filings

Apyx Medical Quarterly report: Q1 2026

Apyx Medical has published its Q1 2026 quarterly earnings report on May 7, 2026.

12 days ago - Filings

Apyx Medical Corporation Reports First Quarter 2026 Financial Results

CLEARWATER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON...

12 days ago - GlobeNewsWire

Weight-loss revolution sparks new appetite for aesthetics firms

Aesthetic firms are betting that a growing pool of patients experiencing loose skin and facial volume loss from GLP-1 obesity drugs will fuel a new wave of demand, as the sector heads into first-quart...

Other symbols: EOLSESTAINMD
15 days ago - Reuters

Apyx Medical Corporation to Release First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026

CLEARWATER, Fla., April 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the ...

26 days ago - GlobeNewsWire

Renuvion wins 2026 NewBeauty Award for "Best Minimally Invasive Skin Tightener"

Renuvion continues to lead in minimally invasive body contouring as the trusted solution for loose skin. CLEARWATER, Fla.

6 weeks ago - PRNewsWire

Apyx Medical price target raised to $6 from $5 at Craig-Hallum

Craig-Hallum raised the firm’s price target on Apyx Medical (APYX) to $6 from $5 and keeps a Buy rating on the shares. The firm notes the company reported a strong…

2 months ago - TheFly

Apyx Medical Transcript: The Citizens Life Sciences Conference 2026

AYON, a fully integrated surgical aesthetics system, is driving strong growth and market interest by consolidating multiple technologies and addressing new demand from GLP-1-induced skin laxity. The company is achieving operational efficiencies, expanding internationally, and expects 17%-19% revenue growth this year.

2 months ago - Transcripts

Apyx Medical upgraded to Buy from Neutral at BTIG

BTIG analyst Sam Eiber upgraded Apyx Medical (APYX) to Buy from Neutral with a $6 price target The firm cites positive early momentum with the Ayon launch, growing demand for…

2 months ago - TheFly

Apyx Medical Earnings Call Transcript: Q4 2025

Record Q4 revenue and strong AYON system adoption drove 35% year-over-year growth, with positive EBITDA and improved cash flow. 2026 guidance projects continued double-digit growth in surgical aesthetics, with plans for international expansion and further product enhancements.

2 months ago - Transcripts

Apyx Medical Annual report: Q4 2025

Apyx Medical has published its Q4 2025 annual report on March 10, 2026.

2 months ago - Filings

Apyx Medical Earnings release: Q4 2025

Apyx Medical released its Q4 2025 earnings on March 10, 2026, summarizing the period's financial results.

2 months ago - Filings

Apyx Medical sees FY26 revenue $57.5M-$58.5M, consensus $56.05M

Total revenue in the range of $57.5 million to $58.5 million. This is compared with $52.8 million reported for the year ended December 31, 2025. The Company expects operating expenses…

2 months ago - TheFly

Apyx Medical reports Q4 EPS (3c), consensus (6c)

Reports Q4 revenue $19.16M, consensus $19.12M. “We are making steady progress scaling the U.S. commercial program for AYON following its official launch in September 2025, with early customer interest...

2 months ago - TheFly

Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results

CLEARWATER, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AY...

2 months ago - GlobeNewsWire

Apyx Medical Corporation to Participate in The Citizens Life Sciences Conference

CLEARWATER, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the A...

3 months ago - GlobeNewsWire

Apyx Medical reports preliminary Q4 revenue $19M-$19.2M, consensus $17.47M

“We are excited by AYON’s commercial launch, which delivered immediate momentum and contributed to a strong fourth quarter, including an increase of approximately 51% in revenue for our Surgical Aesth...

4 months ago - TheFly

Apyx Medical Corporation Reports Preliminary, Unaudited, Fourth Quarter and Full Year 2025 Revenue Results

CLEARWATER, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the A...

4 months ago - GlobeNewsWire

Apyx Medical initiated with a Buy at Roth Capital

Roth Capital initiated coverage of Apyx Medical (APYX) with a Buy rating and $6 price target The company’s Renuvion technology is the only approved device for treatment of loose skin…

5 months ago - TheFly

Apyx Medical announces approval, commercial launch of Apyx One console

Apyx Medical (APYX) announced the approval and commercial launch of the Apyx One console and single-use handpieces in South Korea following the recent regulatory approval by the Ministry of Food…

5 months ago - TheFly